Related Experiment Videos
Proteomic approaches to tumor marker discovery
Alex J Rai1, Zhen Zhang, Jason Rosenzweig
1Department of Pathology, the Johns Hopkins University School of Medicine, Baltimore, Md 21287, USA.
Archives of Pathology & Laboratory Medicine
|November 29, 2002
Summary
New plasma biomarkers show promise for ovarian cancer detection. Combining these with CA125 significantly improves sensitivity and specificity, offering a complementary approach to current tumor markers.
Area of Science:
- Proteomics and Bioinformatics
- Biomarker Discovery
- Ovarian Cancer Diagnostics
Background:
- Current ovarian cancer tumor markers lack sufficient sensitivity and specificity.
- High-throughput proteomic profiling and bioinformatics enable rapid screening of potential biomarkers in bodily fluids.
Purpose of the Study:
- To assess the utility of plasma protein profiles for identifying novel ovarian cancer biomarkers.
- To determine if these biomarkers can improve ovarian cancer detection rates.
Main Methods:
- Plasma samples from ovarian cancer patients and healthy controls were analyzed using proteomic profiling and bioinformatics.
- Potential biomarkers were identified and their discriminatory performance was evaluated against CA125.
Main Results:
- A panel of 7 biomarkers was selected, with 3 further identified.
- A combination of 4 biomarkers, when used with CA125, significantly improved detection performance.
- The combined index achieved 94% sensitivity at 94% specificity, outperforming CA125 alone (81% sensitivity).
Conclusions:
- Proteomic profiling and bioinformatics offer an effective strategy for screening potential tumor markers.
- A panel of plasma biomarkers was identified with discriminatory power complementary to CA125 for ovarian cancer detection.
- Further studies are needed to validate these novel biomarkers.